Mazen Mislmani, MD

Mazen Mislmani, MD
Mazen Mislmani, MD

Clinical Assistant Professor, Department of Medicine

Biosketch

Mazen Mislmani, MD is a physician at West Michigan Cancer Center. Dr. Mislmani earned his medical degree in 2010 from Wayne State University School of Medicine. He went on to complete a radiation oncology residency in 2015 from Seidman Cancer Center/Case Western Reserve University in Cleveland, OH.

  • Board Certification
    • American Board of Radiology (Radiation Oncology)

  • 汤头条app and Training
    • Residency 2015, Radiation Oncology, Seidman Cancer Center, Case Western Reserve University
    • Internship 2011, Family Medicine, Crittenton Hospital, Wayne State University
    • MD 2010, School of Medicine, Wayne State University
    • BS 2004, Radiation Therapy, Magna Cum Laude, Wayne State University School of Medicine,

  • Research
    • Radiation Oncology

  • Publications

    • Dykstra M.P., Regan S.N., Yin H.(., McLaughlin P.W., Boike T., Bhatt A., Zaki M., Kendrick D., Mislmani M., Paluch S., Litzenberg D.W., Mietzel M.A., Narayana V., Smith A., Heimburger D.K., Schipper M.J., Jackson W.C., Dess R.T. International Journal of Radiation Oncology Biology Physics. 2024

    • Chen A.Y., Sassic J.K., Mislmani M., Hoekstra A.V. High-dose palliative radiation therapy for solitary recurrence of ovarian cancer in the brain: A case report Journal of Reproductive Medicine. 2020;65:320-324.

    • Awan M.J., Dorth J., Mani A., Kim H., Zheng Y., Mislmani M., Welford S., Yuan J., Wessels B.W., Lo S.S., Letterio J., Machtay M., Sloan A., Sohn J.W. Technology in Cancer Research and Treatment. 2017;16(2):203-210.

    • Brett-Morris A., Mislmani M., Welford S.M. SAT1 and glioblastoma multiforme: Disarming the resistance Molecular and Cellular Oncology. 2015;2(3)

    • Kunos C.A., Sherertz T.M., Mislmani M., Ellis R.J., Lo S.S., Waggoner S.E., Zanotti K.M., Herrmann K., Debernardo R.L. Phase I trial of carboplatin and gemcitabine chemotherapy and stereotactic ablative radiosurgery for the palliative treatment of persistent or recurrent gynecologic cancer Frontiers in Oncology. 2015;5(JUN)

    • Mislmani M., Frasure H., Suppiah S., Fabien J., Lo S., Debernardo R., Kunos C. Future Oncology. 2014;10(2):241-248.